| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
cis-Ferulic acid 4-O-β-D-glucopyranoside primarily targets protein tyrosine phosphatase 1B (PTP1B), a key negative regulator of insulin receptor signaling. By inhibiting PTP1B, the compound enhances insulin signaling and promotes glucose uptake in insulin-responsive tissues. The compound also demonstrates potent antioxidant activity, which may contribute to its overall therapeutic potential by reducing oxidative stress and protecting cells from damage. The dual PTP1B inhibitory and antioxidant activities make this compound particularly interesting for diabetes research.
|
|---|---|
| ln Vitro |
In vitro, cis-Ferulic acid 4-O-β-D-glucopyranoside demonstrates potent inhibition of PTP1B phosphatase activity. The compound shows concentration-dependent inhibition in biochemical assays using purified PTP1B enzyme. The compound also exhibits significant antioxidant activity, which can be measured using standard antioxidant assays such as DPPH radical scavenging or ABTS assays. The combination of PTP1B inhibition and antioxidant activity suggests potential synergistic benefits for metabolic health.
|
| ln Vivo |
In vivo activity data for cis-Ferulic acid 4-O-β-D-glucopyranoside are limited, as the compound is primarily studied in vitro. Based on its PTP1B inhibitory and antioxidant mechanisms, the compound is expected to improve glucose metabolism, insulin sensitivity, and oxidative stress in animal models of diabetes and metabolic disorders. However, detailed pharmacokinetic and efficacy studies in animal models have not been extensively reported. Further in vivo studies are needed.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for cis-Ferulic acid 4-O-β-D-glucopyranoside typically involves measuring PTP1B activity using a synthetic substrate such as p-nitrophenyl phosphate (pNPP). Purified recombinant human PTP1B enzyme is incubated with varying concentrations of the compound (0.1-100 µM) in assay buffer at 37°C for 10-15 minutes. The reaction is initiated by adding the substrate, and after incubation, the reaction is stopped. Absorbance at 405 nm is measured, and IC50 values are calculated. For antioxidant assays, DPPH or ABTS radical scavenging protocols are used.
|
| Cell Assay |
For in vitro cell-based assays, insulin-responsive cell lines or cells exposed to oxidative stress are cultured and treated with cis-Ferulic acid 4-O-β-D-glucopyranoside at concentrations ranging from 1-100 µM for 24-48 hours. PTP1B activity is measured in cell lysates using a phosphatase activity assay kit. Insulin signaling is evaluated by Western blot analysis of phosphorylated insulin receptor and Akt. Oxidative stress markers such as reactive oxygen species and lipid peroxidation are measured.
|
| Animal Protocol |
In vivo animal studies for cis-Ferulic acid 4-O-β-D-glucopyranoside have not been extensively reported. Based on the compound's mechanisms as a PTP1B inhibitor and antioxidant, potential in vivo studies would involve administration to diabetic or obese mouse models via oral gavage or intraperitoneal injection at doses ranging from 1-50 mg/kg. Efficacy would be assessed by measuring blood glucose levels, insulin sensitivity, and oxidative stress markers. Tissue samples would be collected for analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of cis-Ferulic acid 4-O-β-D-glucopyranoside have not been fully characterized. Molecular weight is 356.32 and molecular formula is C₁₆H₂₀O₉. CAS number is 94942-20-8. The compound appears as a white crystalline powder. Detailed pharmacokinetic parameters such as bioavailability, half-life, and protein binding have not been reported. Stability in solution may be limited.
|
| Toxicity/Toxicokinetics |
Toxicology data for cis-Ferulic acid 4-O-β-D-glucopyranoside are limited. As a natural phenolic glycoside, the compound is generally considered to have low toxicity, but comprehensive toxicology studies have not been conducted. The compound's antioxidant properties suggest a favorable safety profile. However, potential off-target effects and chronic toxicity remain to be evaluated. Standard in vitro toxicity assays should be performed for safety assessment.
|
| References | |
| Additional Infomation |
Cis-ferulic acid 4-O-β-D-glucopyranoside has been reported in Onobrychis viciifolia and Equisetum hyemale, and available data are available.
cis-Ferulic acid 4-O-β-D-glucopyranoside (compound 7) is a phenolic glycoside from Siberian white thorn with potent PTP1B inhibitory activity and antioxidant effects. The compound's dual mechanism of action makes it a valuable tool for studying insulin signaling, oxidative stress, and metabolic regulation. It shows potential for diabetes and metabolic research applications. The compound is intended for research use only and is not approved for therapeutic applications. |
| Molecular Formula |
C16H20O9
|
|---|---|
| Molecular Weight |
356.324605941772
|
| Exact Mass |
356.11
|
| CAS # |
94942-20-8
|
| PubChem CID |
9820054
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
25
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C=CC(=C1)/C=C\C(=O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
|
| InChi Key |
IEMIRSXOYFWPFD-QEQKPWIDSA-N
|
| InChi Code |
InChI=1S/C16H20O9/c1-23-10-6-8(3-5-12(18)19)2-4-9(10)24-16-15(22)14(21)13(20)11(7-17)25-16/h2-6,11,13-17,20-22H,7H2,1H3,(H,18,19)/b5-3-/t11-,13-,14+,15-,16-/m1/s1
|
| Chemical Name |
(Z)-3-[3-methoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8065 mL | 14.0323 mL | 28.0647 mL | |
| 5 mM | 0.5613 mL | 2.8065 mL | 5.6129 mL | |
| 10 mM | 0.2806 mL | 1.4032 mL | 2.8065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
